AvalehtDCTH • NASDAQ
add
Delcath Systems Inc
11,00 $
Pärast sulgemist:(0,00%)0,00
11,00 $
Suletud: 30. aug, 16:30:17 GMT −4 · USD · NASDAQ · Välistus
Viimane sulgemishind
10,77 $
Tänane vahemik
10,42 $ - 11,16 $
Aasta vahemik
2,25 $ - 11,75 $
Turuväärtus
307,99 mln USD
Keskmine maht
305,64 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Käive | 7,77 mln | 1 468,89% |
Põhitegevusega seonduv kulu | 10,16 mln | 21,78% |
Puhastulu | −13,74 mln | −90,79% |
Puhaskasumimarginaal | −176,94 | 87,84% |
Puhaskasum aktsia kohta | −0,48 | 17,24% |
EBITDA | −3,88 mln | 51,32% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 19,91 mln | 36,91% |
Kogu vara | 33,91 mln | 61,11% |
Kõik kohustused | 13,91 mln | −20,56% |
Kogu omakapital | 20,00 mln | — |
Emiteeritud aktsiate arv | 28,00 mln | — |
Hinna ja väärtuse suhe P/B | 71,80 | — |
Varade tasuvus | −27,94% | — |
Kapitali tasuvus | −35,67% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −13,74 mln | −90,79% |
Põhitegevuse rahakäive | −4,45 mln | 53,87% |
Investeeringute raha | 10,28 mln | 25 810,00% |
Finantseerimise raha | −2,85 mln | −40 871,43% |
Raha ja raha ekvivalentide muutus | 2,97 mln | 130,70% |
Tasuta rahavoog | −2,46 mln | 62,43% |
Teave
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Tegevjuht
Asutatud
1988
Veebisait
Töötajate arv
76